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Frailty denotes a multidimensional syndrome that gives rise to vulnerability to stressors and 
leads to an increase of the age-related decline of different physiological systems and cog-
nitive abilities. Aging-related alterations of the immune system may compromise its com-
petence culminating in a chronic low-grade inflammation state. Thus, it has been proposed 
that frailty is associated with alterations in the concentration of pro-inflammatory molecules 
and in different lymphocyte subpopulations. To provide further support to the validity of that 
hypothesis, we conducted a cross-sectional study in a population of Spanish older adults 
(N = 259, aged 65 and over) classified according to their frailty status. Biomarkers analyzed 
included percentages of several lymphocyte subsets and several inflammation mediators, 
namely concentrations of interleukin 6 (IL6), C-reactive protein (CRP), tumor necrosis 
factor α (TNFα), and 75 kDa soluble TNFα receptor II (sTNF-RII). Reference ranges for the 
inflammation mediators were established for the first time in robust older adults. A signifi-
cant increase in the CD4+/CD8+ ratio and a significant decrease in the % CD19+ cells were 
observed in the frail group. Progressive increases with frailty severity were obtained in all 
inflammatory mediator concentrations, especially notable for IL6 and sTNF-RII. Area under 
the receiver-operating characteristic curve obtained for sTNF-RII (0.90, 95% CI 0.85–0.94, 
P < 0.001) indicates a high accuracy in the predictive value of this biomarker for frailty. 
Although results from the current study revealed limited strength associations between 
frailty and the lymphocyte subsets assessed, data obtained for the inflammatory mediators 
provide further support to involvement of inflammaging in frailty status in older adults.
Keywords: c-reactive protein, interleukin 6, frailty, inflammaging, lymphocyte subpopulations, tumor necrosis 
factor α, soluble TnFα receptor ii
inTrODUcTiOn
Nowadays, world population is experiencing an unstoppable aging situation due to the increasing 
life expectancy and low birth rates, and this trend is evident from the most developed countries to 
the lowest income regions (1). The 2015 Aging Report by the European Commission has estimated, 
comparing European population in 2013 and 2060, that young people (aged 0–14) will remain 
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constant (around 15%), that people aged 15–64 will decline 
slightly from 66 to 57%, but older adults will increase notably: 
from 18 to 28% those aged 65 and over, and from 5 to 12% those 
aged 80 and over; this last group will almost become as numerous 
as the young population in 2060 (2). This rise in the older popula-
tion, together with the associated sanitary, social, and economic 
implications, has increased the global interest in the study of 
aging processes and age-related conditions (3).
Due to the fact that aging manifestations are very hetero-
geneous, chronological age is not a proper indicator of aging. In 
this context, the term frailty has been coined as a more precise 
measurement of aging signs and symptoms. Frailty denotes a 
multidimensional syndrome of loss of energy, physical ability, 
cognition, and health that gives rise to vulnerability to stressors 
(4). This vulnerability leads to a significant increase of the age-
related decline of different physiological systems and cognitive 
abilities, and eventually to comorbidity, disability, hospitalization, 
and death in older adults (5). Frailty-associated physiological 
dysregulation involves multi-organ systems including the muscu-
loskeletal, immune, endocrine, hematologic, nervous, and cardi-
o vascular systems (6, 7). Moreover, the existence of an association 
between frailty and the development of several age-related dis-
eases, such as cardiovascular disease (8), cancer (9), osteoporosis 
(10), and Alzheimer’s disease (11) is currently accepted.
One of the most commonly used criteria to assess frailty are 
those developed by Linda Fried and colleagues (12). Due to their 
simplicity and ease of implementation, it is the most widely used 
in clinic and research on frailty. Definition according to these 
criteria represents a phenotypic description of frailty based on 
the presence or absence of five very specific components related 
to physical fitness and metabolism (muscle weakness, low gait 
speed, unintentional weight loss, exhaustion, and low physical 
activity). Based on Fried’s definition, the prevalence of frailty 
in community-dwelling Spanish older populations is 3.7–16.3% 
(13–15), but it can reach 68.8% in institutionalized older people 
(16). Since it has been demonstrated that frailty is potentially pre-
ventable and can be even reverted in its primary stages (17, 18), 
early detection of frail subjects is critical.
Inflammation is a necessary response of the immune system 
to different harmful conditions such as infection and injury. 
This acute and transient immune response resulting in elevated 
production of cytokines and acute phase proteins facilitates the 
repair, turnover, and adaptation of many tissues. But when inflam-
mation becomes chronic, often associated with aging or age- 
related diseases, it seems to have detrimental effects (19). Aging- 
related alterations of the immune system that compromise its 
competence are defined as “immunosenescence,” phenomenon 
partially responsible for increased autoimmunity, raised preva-
lence, and severity of infectious diseases, and lower efficacy of 
vaccination in older adults (20). The main feature of immuno-
senescence is the change in the cellular composition of the T-cell 
compartment, including a decrease in the number of naive 
phenotype cells, in association with an increase in the number 
of memory phenotype cells, all of which culminate a pro-inflam-
matory state, called “inflammaging,” diminishing the immune 
system capacity to respond to new antigens (21). This chronic 
low-grade inflammation is characterized by increases in the levels 
of pro-inflammatory cytokines such as interleukin 6 (IL6), tumor 
necrosis factor alpha (TNFα), and its soluble receptors [sTNF-RI 
and 75 kDa soluble TNFα receptor II (sTNF-RII)], as well as acute 
phase proteins such as C-reactive protein (CRP), which impair the 
main tenance of immunological homeostasis (22).
Inflammaging has been postulated to be an underlying mech-
anism of frailty, acting either directly or indirectly through its 
negative influence on other physiological systems (23, 24). Thus, 
studies testing the hypothesis that frailty is associated with 
alterations in the concentration of immune activation markers, 
pro-inflammatory molecules, and in different lymphocyte sub-
populations are increasing in the last years (25–29), although 
clear definitive conclusions have not been reached yet.
Hence, in order to provide further support to the validity of 
that hypothesis and to increase the body of evidence connecting 
frailty within inflammaging and immunosenescence biomarkers, 
we conducted a cross-sectional study in a population of older 
adults (N =  259, aged 65 and over) classified according to their 
frailty status following Fried’s criteria (12). Biomarkers analyzed 
included percentages of several lymphocyte subsets (CD3+, CD4+, 
CD8+, CD19+, and CD16+56+), and concentrations of IL6, CRP, 
sTNF-RII, and TNFα. Besides, the influence of clinical parameters, 
namely, nutritional and functional status, was also explored.
MaTerials anD MeThODs
ethics statement
Ethical approval was obtained from the University of A Coruña 
Ethics Committee (reference number CE 18/2014). The study was 
conducted according to the Helsinki Declaration and Interna-
tional Conference of Harmonization guidelines. Written informed 
consent was obtained from all study participants, or their relatives 
in case of inability.
study subjects
In total, 259 individuals aged 65–102 years were recruited from 
Galicia, North-western Spain. They were contacted through asso-
ciations of older or retired people, day-care centers, and nursing 
homes. Table  1 shows the general characteristics of the study 
population, classified according to the frailty status. The small 
number of current smokers and ex-smokers (N = 5 and N = 49, 
respectively) motivated to join them all in a new category, “ever 
smokers.” Similarly, malnourished individuals (N = 14) and indi-
viduals at risk of malnutrition (N = 80) were included together 
in a single category.
Participants were individually assessed at the centers, by inter-
viewers specially trained in clinical evaluation to unify criteria, 
and all completed a questionnaire to assess demographic, lifestyle, 
and medical information. Participants were excluded if they did 
not possess the necessary skills to be assessed or denied signing 
the informed consent. Exclusion criteria also included taking 
medications included in the Anatomical Therapeutic Chemical 
category L (antineoplastic or immunomodulating agents) (30), 
and having any chronic infection, autoimmune disease, or cancer, 
since these conditions are directly related to immune system 
dysfunctions and, consequently, they could act as confounders.
Table 1 | Description of the study population.
non-frail Pre-frail Frail P
Total individuals N (%) 40 (15.4) 131 (50.6) 88 (34.0)
gender N (%)
Males 27 (67.5) 36 (27.5) 22 (25.0) <0.001b
Females 13 (32.5) 95 (72.5) 66 (75.0)
Age (years-old)a 73.2 ± 5.5 (65–85) 77.05 ± 7.7 (65–100) 85.8 ± 7.9 (65–102) <0.001c
65–69 13 (32.5) 29 (22.1) 2 (2.3) <0.001b
70–74 11 (27.5) 26 (19.9) 4 (4.6)
75–79 10 (25.0) 24 (18.3) 13 (14.9)
80–84 5 (12.5) 27 (20.6) 14 (16.1)
≥85 1 (2.5) 25 (19.1) 54 (62.1)
smoking habit N (%)
Non-smokers 22 (55.0) 102 (78.5) 76 (90.5) <0.001b
Ever smokers 18 (45.0) 28 (21.5) 8 (9.5)
No. cigarettes/daya 16.1 ± 8.8 (3–40) 15.7 ± 13.9 (2–60) 31.4 ± 15.7 (2–60) 0.020c
Years smokinga 19.4 ± 9.1 (10–34) 30.4 ± 18.7 (4–66) 29.3 ± 18.2 (6–52) 0.154c
comorbidity N (%)
No comorbidity 34 (85.0) 92 (70.2) 52 (59.8) 0.015b
Comorbidity 6 (15.0) 39 (29.8) 35 (40.2)
living conditions N (%)
Family home 40 (100.0) 113 (86.3) 5 (5.7) <0.001b
Family home + daycare center – 4 (3.1) 23 (26.1)
Nursing home – 14 (10.6) 60 (68.2)
aMean ± SD (range).
bChi-square test (bilateral).
cANOVA test (bilateral).
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Whole blood samples were obtained by venipuncture and 
collected into vacutainer tubes containing ethylenediaminetet-
raacetic acid between 9:30 h and 12:30 h and transported imme-
diately to the lab. Fresh whole blood samples were used for the 
analysis of lymphocyte subsets. After centrifugation at 2,300 rpm 
for 10 min to obtain plasma, samples were aliquoted and stored 
at −80°C until analysis of inflammatory mediators. All samples 
were coded at the moment of collection to ensure a “blind” study.
Frailty status
Frailty status of each participant was assessed according to the 
five phenotypic criteria proposed by Fried et al. (12). These cri-
teria are based on the presence or absence of specific phenotypic 
components:
(i) Unintentional weight loss (i.e., not due to dieting or exercise): 
at least 4.5 kg in the past year,
(ii) Self-reported exhaustion: identified by two questions from 
the Spanish version (31) of the modified 10-item Center for 
Epidemiological Studies-Depression (CES-D) scale (32),
(iii) Weakness: grip strength in the lowest 20% at baseline, 
adjusted for gender and body mass index,
(iv) Slow walking speed: the slowest 20% at baseline, based on 
time to walk 15 ft, adjusting for gender and standing height, 
and
(v) Low physical activity: the lowest 20% at baseline, based on a 
weighted score of kilocalories expended per week, calculated 
according to the Spanish validation (33) of the Minnesota 
Leisure Time Activity questionnaire (34) according to each 
participant’s report, and adjusting for gender.
Frailty was defined as the presence of three or more of these 
characteristics, pre-frailty in case of one or two of them present, 
and the absence of all five determined a non-frail state.
comorbidity
General comorbidity and number of comorbid diseases were 
assessed by means of the Charlson’s comorbidity index (35). For 
each subject, an age-adjusted score was computed, coding the 
absence of comorbid diseases as 0, and the presence as 1–6.
lymphocyte subpopulations
Three-color direct immunofluorescence surface marker analysis 
was carried out by flow cytometry as previously described (36) to 
determine peripheral blood lymphocyte phenotypes as follows: 
T lymphocytes (CD3+), T-helper lymphocytes (CD3+ and CD4+), 
T-cytotoxic lymphocytes (CD3+ and CD8+), B lymphocytes 
(CD19+), and NK cells (CD3− and CD16+56+). Samples were 
analyzed in a FACScalibur flow cytometer (Becton Dickinson) 
using CellQuest Pro software (Becton Dickinson). Lymphocytes 
were gated on the basis of size and complexity, and fluorescence 
data were obtained to determine percentages of the different 
lymphocyte subsets, acquiring a minimum of 104 events in the 
lymphocyte window.
circulating inflammatory Molecules
Plasma levels of IL6, CRP, TNFα, and sTNF-RII were measured 
by quantitative sandwich enzyme-linked immunosorbent assays 
with commercial kits (all from R&D Systems Inc., Minneapolis, 
MN, USA), according to the manufacturer’s instructions. Samples 
required a 100-fold dilution for analysis of CRP, and a 10-fold 
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dilution for analysis of sTNF-RII. Regarding precision of the 
assays, maximum intra- and inter-assay coefficients of variation 
were 4.2 and 6.4% for IL6, 8.6 and 7.0% for CRP, 3.0 and 8.4% for 
TNFα, and 4.8 and 5.1% for sTNF-RII, respectively.
Tumor necrosis factor α concentration could only be evaluated 
in specimens from 88 individuals (20 non-frail, 38 pre-frail, and 
30 frail), of whom sufficient residual plasma volume was avail-
able. Spectrophotometric measurements were conducted in a 
Powerwave X microplate reader (Bio-Tek Instruments) equipped 
with kinetic analysis software (KC4 v.2.5, Bio-Tek Instruments).
statistical analysis
A general description of the study population, classified accord-
ing to the frailty status, was carried out by univariate analysis. 
Sociodemographic, lifestyle, and clinical characteristics were 
compared in the three groups of subjects, applying analysis of 
variance (ANOVA) for continuous variables and Chi-square test 
for categorical variables (Table 1).
The effect of frailty status on the immune biomarkers deter-
mined was preliminarily assessed by ANOVA and Tuckey’s post 
hoc test. Data from % CD3+, % CD4+, % CD16+56+, and TNFα 
followed a normal distribution (Kolmogorov–Smirnov goodness-
of-fit test). A log-transformation of the data was applied to % 
CD8+, % CD19+, IL6, and CRP to achieve a better approxima-
tion to the normal distribution. No improvement was achieved 
with transformation for CD4+/CD8+ratio and sTNF-RII, so they 
were analyzed using the Kruskal–Wallis test with Bonferroni’s 
correction.
Values of IL6, CRP, sTNF-RII and TNFα obtained in non-frail 
and pre-frail individuals were used for calculating reference 
ranges. They were defined as mean ± 2 SD for those parameters 
following a Gaussian distribution. For data not normally distri-
buted (sTNF-RII), reference range was calculated as the central 
95% of the area under the distribution curve (from 2.5 to 97.5%).
Linear regression analysis was applied to estimate the effect of 
frailty status on the immune parameters. Models were run with 
log-transformed data, adjusting for age, gender, smoking habit 
(never/ever smokers) and comorbidity. All results are shown as 
mean ratios and 95% confidence intervals (95% CI).
Correlation coefficients (Spearman’s rho) were calculated in 
order to estimate the possible associations between immune bio-
markers. Receiver-operating characteristic (ROC) curves were 
computed to assess the inflammatory biomarkers discrimina-
ting ability. Statistical analyses were conducted by means of the 
STATA/SE software package V. 12.0 (StataCorp LP) and the IBM 
SPSS software package V. 20 (SPSS, Inc.). Statistical significance 
was established at a P value lower than 0.05.
resUlTs
Study population comprised 259 older adults, aged from 65 to 
102 years; frail subjects were significantly older, with 62% aged 
over 85 years (Table 1). Female gender was less prevalent in the 
non-frail group (approximately 1:2), but gender proportions 
were opposite in the pre-frail and frail groups. Proportion of 
smokers decreased with increasing frailty severity; frail smokers 
consumed a higher amount of cigarettes per day, but the number 
of years smoking was not significantly different among the three 
groups of smokers. Only 10% of non-frail individuals were at 
risk of malnutrition, with no one malnourished. The rate of 
malnourishment increased, and consequently the MNA-SF score 
decreased, with frailty severity. There were only two subjects 
(5%) in the non-frail group with ADL dependence, while ADL 
depen dence was present in 94% of frail subjects. Similarly, com-
orbidity increased with frailty, from 15% in the non-frail group 
to 40% in the frail group. Regarding living conditions, all non-
frail individuals lived at family homes, while nearly 70% of frail 
participants lived in nursing homes.
Figure 1 shows values of the immune parameters determined 
in the three groups of older adults, with univariate analysis com-
parison. The only lymphocyte subset showing significant changes 
was % CD19+ cells, which decreased significantly in the group of 
frail subjects. On the contrary, significant increases with frailty 
were observed for IL6, CRP, sTNF-RII and TNFα concentrations. 
No differences were obtained in these markers between non- 
frail and pre-frail individuals, except for sTNF-RII.
Reference ranges for lymphocyte subpopulations in non-frail 
older adults were described previously (36). When comparing 
the current results with those reference ranges, 91–97% of values 
obtained for the different subsets in the non-frail group, 94–97% 
of values in the pre-frail group, and 83–97% of values in the frail 
group fell within the established ranges, with no significant differ-
ences between groups for any particular subset. Reference ranges 
in robust older adults for IL6, CRP, sTNF-RII and TNFα had not 
been described so far. Thus, concentrations obtained in the non-
frail and pre-frail subjects were used for estimating the upper 
and lower limits of the corresponding reference ranges (Table 2), 
since no significant differences were observed between these 
two groups, except in the case of sTNF-RII, where differences 
with frail individuals were much more remarkable. Percentages 
of frail subjects with values exceeding the corresponding refer-
ence ranges for the different parameters oscillated from 9 to 19%, 
with no value below the range in any case.
In the analysis of the associations between immune biomark-
ers, notable and significant correlations were obtained between 
CRP and IL6 (r = 0.405, P < 0.001), between CRP and sTNF-RII 
(r = 0.339, P < 0.001), between sTNF-RII and TNFα (r = 0.433, 
P < 0.001), between TNFα and IL6 (r = 0.344, P < 0.01), and 
between IL6 and sTNF-RII (r = 0.250, P < 0.001).
Results obtained from the multivariate statistical analyses 
regarding frailty status are shown in Table 3. A significant increase 
in the CD4+/CD8+ ratio and a significant decrease in the % CD19+ 
cells were observed in the frail group. Moreover, and according 
to the results from the univariate analysis, progressive increases 
with frailty severity were obtained in all inflammatory mediator 
concentrations; being especially remarkable the 70% increase of 
IL6 and the twofold increase of sTNF-RII in the frail subjects with 
regard to the non-frail participants.
Figure 2 shows the ROC curves computed to test the predic-
tive value of the inflammatory molecules for frailty (except for 
TNFα due to the much lower data available), using the non-frail 
group as the standard. Areas under the curves obtained were 0.64 
(95% CI 0.56–0.71, P <  0.01) for IL6, 0.60 (95% CI 0.52–0.68, 
FigUre 1 | Results of immunological biomarkers in the study group, classified according to frailty status (univariant analysis). Bars represent mean standard error. 
*Statistically different from non-frail, #statistically different from pre-frail (Tukey’s test or Bonferroni’s correction). Abbreviations: CRP, C-reactive protein,  
IL6: interleukin 6, TNFα: tumor necrosis factor alpha, sTNF-RII, soluble tumor necrosis factor alpha receptor II.
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P < 0.05) for CRP, 0.90 (95% CI 0.85–0.94, P < 0.001) for sTNF-
RII, and 0.66 (95% CI 0.54–0.77, P < 0.05) for TNFα. A sTNF-RII 
concentration of 3,461.3 pg/ml had the optimal predictive value 
for frailty, with a sensitivity of 0.94 and a specificity of 0.76.
DiscUssiOn
Use of biomarkers as feasible endpoints has been proposed for 
frailty identification (37), since they would provide a more accurate 
Table 3 | Effect of frailty status on lymphocyte subsets and inflammatory mediators; models adjusted by age, sex, smoking habit, and comorbidity.
Mean ratio 95% ci Mean ratio 95% ci Mean ratio 95% ci Mean ratio 95% ci Mean ratio 95% ci
% cD3+ % cD4+ % cD8+ cD4+/cD8+ % cD19+
Frailty status
Non-frail 1.00 1.00 1.00 1.00 1.00
Pre-frail 1.00 (1.00–1.17) 1.09 (0.86–1.38) 1.00 (0.81–1.24) 1.09 (0.77–1.55) 0.82 (0.65–1.04)
Frail 0.98 (0.94–1.03) 1.31 (0.98–1.76) 0.82 (0.64–1.06) 1.66* (1.09–2.53) 0.73* (0.55–0.97)
% cD16+56+ il6 crP sTnF-rii TnFα
Non-frail 1.00 1.00 1.00 1.00 1.00
Pre-frail 1.07 (0.85–1.35) 1.15 (0.75–1.75) 1.19 (0.80–1.75) 1.19* (1.03–1.38) 1.60† (0.96–2.66)
Frail 0.92 (0.70–1.21) 1.70* (1.03–2.83) 1.54† (0.96–2.46) 2.00** (1.68–2.39) 1.68‡ (0.92–3.09)
CI, confidence interval; CRP, C-reactive protein; IL6, interleukin 6; TNFα, tumor necrosis factor alpha; sTNF-RII, soluble tumor necrosis factor alpha receptor II.
*P < 0.05; **P < 0.01; †P = 0.071; ‡P = 0.090.
Bold font means statistically significant data.
Table 2 | Reference ranges of the immune biomarkers analyzed, calculated on 
the basis of results obtained in non-frail and pre-frail subjects.
N reference  
range
% frail subjects  
out of the 
reference range
lower limit Upper limit below above
IL6 (pg/ml) 160 0.20 14.65 0 13.4
CRP (mg/l) 160 0.24 9.90 0 9.3
sTNF-RII (pg/ml) 160 1,322.8 6,563.2 0 18.8
TNFα (pg/ml) 58 0 5.15 0 10.0
CRP, C-reactive protein; IL6, interleukin 6; TNFα, tumor necrosis factor alpha; sTNF-RII, 
soluble tumor necrosis factor alpha receptor II.
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oscillated between 9% in the case of CRP and 19% in the case of 
sTNF-RII. These values were always located above the reference 
range, showing a clear trend to increase with frailty status.
In which regards association of frailty with immune biomark-
ers, our results of lymphocyte subsets showed a slight decrease of 
% CD19+ cells in the frail group—both in the univariate analysis 
and in the linear regression analysis adjusting for age, gender, 
smoking habit, and comorbidity—and an increase of the CD4+/
CD8+ ratio (P < 0.05) in frail subjects in the multivariate analy-
sis, not significant in the univariate analysis. These quite weak 
results point to a limited strength association of these biomarkers 
with frailty. Up to now, very few studies have assessed the link 
between lymphocyte subpopulations and frailty status in older 
adults. De Fanis et al. (39) found a significant association between 
increased CD8+ and decreased CD4+ cell percentages in frail 
subjects regarding to the non-frail group, although sample size 
evaluated was very modest (13 frail vs. 13 non-frail participants). 
Besides, Semba et al. (40) obtained similar results in addition to 
a subsequent significant decrease in the CD4+/CD8+ ratio, with 
a quite larger population size (N = 24, 75, and 28 for non-frail, 
pre-frail, and frail individuals, respectively). None of these studies 
adjusted for possible confounders in the statistical analysis, what 
may account in part for the differences with the current study, 
together with the more restricted sample sizes.
During inflammation, TNFα, IL1, and IL6 are secreted, in that 
order. IL6 then inhibits the secretion of TNFα and IL1, and acti-
vates the production of acute phase reactants from liver (CRP) 
[reviewed in Ref. (41)]. TNFα membrane receptors are shed by 
proteolytic cleavage into circulation as soluble TNFα receptors 
(sTNF-RI and sTNF-RII), which have been shown to be reliable 
measurements for the in  vivo activities of TNFα (42). Results 
from the present study support the idea of an interrelated activa-
tion of the entire inflammatory cascade, since TNFα, sTNF-RII, 
IL6, and CRP concentrations were significantly correlated with 
one another.
Data obtained in this work showed positive influence of frailty 
on IL6, CRP, TNFα, and sTNF-RII concentrations. The only study 
analyzing sTNF-RII concentrations in relation to frailty so far 
found progressive increase of this biomarker with frailty status; 
significance was reached in the group of pre-frail subjects (43). 
detection of frail subjects in early stages, when frailty can still be 
potentially reverted. For the development of frailty-related bio-
markers, physiological processes disturbed in frailty status must 
be explored. Due to the proposed relationship between immune 
system alterations and frailty (38), pro-inflammatory molecule 
concentrations and different lymphocyte subpopulation rates 
could be suitable biomarkers that provide useful information for 
early identification of frailty. Thus, in this study, a set of immune 
biomarkers was assessed in a population of Spanish older adults 
(40 non-frail, 131 pre-frail, and 88 frail), and the possible associa-
tion between biomarkers and frailty status was evaluated.
Since specific reference ranges for lymphocyte subset rates 
were previously reported for older subjects with frailty discarded 
(36), results from the current study were compared with those 
ranges. Most values obtained in the three population groups fell 
within the corresponding reference ranges, and no differences 
were observed regarding frailty severity, indicating a poor con-
nection with frailty for all lymphocyte subpopulations. In spite 
of the previous vast literature analyzing inflammatory mediators 
in populations of older adults, specific reference ranges for this 
age group had not been reported so far. Thus, reference ranges 
for IL6, CRP, sTNF-RII, and TNFα in robust adults (excluding 
the presence of frailty) aged 65 years and over were established in 
this study. Percentages of frail subjects presenting concentrations 
of these biomarkers out of the corresponding reference range 
FigUre 2 | Receiver-operating characteristic (ROC) curves for IL6, CRP,  
and sTNF-RII to predict frailty. Abbreviations: CRP, C-reactive protein; IL6, 
interleukin 6; sTNF-RII, soluble tumor necrosis factor alpha receptor II.
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Still, considerable amount of literature has accumulated concern-
ing the association of high levels of IL6, TNFα, and CRP with 
frailty in older adults in cross-sectional studies. Among works 
assessing all these three biomarkers, some of them reported 
increases in their concentrations with frailty (26–28, 44, 45) and 
with increased risk of death (46). On the contrary, other studies 
did not find such significant associations with frailty (47), or 
obtained mixed results (significance for some markers and no 
effect for others) (38, 48). A recent meta-analysis (49) conducted 
with most abovementioned studies and some others both cross-
sectional and longitudinal concluded that, on the basis of cross-
sectional studies, frailty and pre-frailty are associated with higher 
inflammatory parameter levels, in particular, CRP and IL6, but 
these findings were not confirmed in longitudinal trials, sup-
porting the need of further studies to better understand the role 
of inflammatory markers in frailty status. Our study confirmed 
the involvement of chronic inflammation in frailty in later life; 
particularly strong associations were obtained in the regression 
analysis for IL6 (70% increase in frail subjects with regard to 
non-frail participants), and for sTNF-RII (19% increase in pre-
frail and twofold increase in frail individuals; all three categories 
were significantly different). Moreover, area under the ROC curve 
obtained for sTNF-RII (0.90) indicates a high accuracy in the 
predictive value of this biomarker for frailty. At concentrations 
>3,461.3 pg/ml, frail subjects can be identified with quite high 
sensitivity (0.94) and specificity (0.76).
Numerous studies of older adults showed that levels of 
sev eral inflammatory mediators increase with age even in 
apparently healthy individuals and in the absence of acute 
infection [reviewed in Ref. (50)]. Present results show that 
frailty status in older adults involves an additional increase in 
these mediators, beyond that related to aging. Chronic inflam-
mation has been proposed as a key underlying mechanism 
involved in frailty (23, 24). Inflammatory molecules may 
directly contribute to frailty or its central components (such 
as decreased muscle mass, strength, and power, and slowed 
motor performance). But, as frailty is a multidimensional 
syndrome, the contribution can also be indirect through other 
intermediate pathophysiologic processes, i.e., its detrimental 
effects on other organ systems, such as musculoskeletal and 
endocrine systems, cardiovascular diseases, and nutritional 
dysregulation [reviewed in Ref. (51)].
Increasing evidence suggests that frailty is a useful risk ass-
essment tool for pre-surgery evaluation, for overall immune 
functional decline, in older patients with cardiovascular condi-
tions, or for risk stratification of older patients with cancer 
[reviewed in Ref. (51)]. Hence, the importance of identifying 
frailty is undeniable. The current study suggests that sTNF-RII 
may have clinical applicability as a screening tool for identi-
fying frail subjects, although standardization and replication 
of these results in other populations is necessary before it can 
be used to that aim. A primary limitation of this work includes 
the medical situation of the participants, intrinsically associated 
with studying older adults. Pathologic conditions were present 
in most of them, 15% of robust individuals and 40% of frail 
subjects presented comorbidity, and medications were taken 
to treat these conditions. Although linear regression analyses 
were adjusted for comorbidity and exclusion criteria included 
(i) taking antineoplastic or immunomodulating medications, 
and (ii) having infections, autoimmune disease, or cancer, the 
fact that some of the chronic diseases common in older adults, 
or the associated medications, may have influenced the immune 
parameters evaluated in this study cannot be ruled out.
cOnclUsiOn
In this work, reference ranges for several inflammation mediators 
are established for the first time in older adults in the absence of 
frailty according to Fried’s criteria. Associations found between 
inflammatory molecules confirm their interrelationship in the 
immune activation cascade. Although results from the current 
study revealed limited strength associations between frailty and 
the lymphocyte subsets assessed, data obtained for the different 
inflammatory mediators provide additional reinforcement to 
the widely established hypothesis that inflammaging is involved 
in frailty status in older adults. Hence, frail subjects present an 
additional degree of chronic inflammation manifestations than 
what could be expected only according to the normal aging 
process. This association was more intensively manifested in 
IL6 and sTNF-RII. This last biomarker showed a high accuracy 
for predicting frailty.
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